Results from a phase 2 clinical trial on phosphodiesterase 4 (PDE4) inhibition (BI1015550) showed that, regardless of whether patients received anti-fibrotic drugs, BI1015550 treatment can prevent pulmonary function decline in IPF patients within 12 weeks [62]. The gene discussed is PDE4A; the disease is idiopathic pulmonary fibrosis.